文献速递肝病

全球MASLD无创检测性能差异:G-MASLD研究解读

Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study.
PubMed 文献 · Hepatology · 2025-10-08

G-MASLD研究纳入41国17792例经肝活检的MASLD患者,评估FIB-4、ELF、LSM及复合评分预测纤维化的性能。常见无创检测的诊断性能存在地区差异,Agile-3+与Agile-4复合评分准确性最高。

要点

  • FIB-4预测进展期纤维化汇总AUC为0.80,拉丁美洲最低(0.75),MENA最高(0.84)。
  • LSM预测进展期纤维化汇总AUC为0.84,除北美(0.78)外各地区表现相似。
  • Agile-3+预测进展期纤维化AUC为0.87,Agile-4预测肝硬化AUC为0.90,为最准确的无创检测。

核心结论

  • 常见无创检测对MASLD纤维化的诊断性能在全球不同地区存在差异。
  • 在G-MASLD大样本中,最准确的无创检测为Agile-3+和Agile-4复合评分。

研究设计与样本

  • 通过全球NASH理事会协作(G-MASLD)纳入有肝活检和无创检测数据的MASLD患者。
  • 共纳入来自41个国家的17792例MASLD患者。

主要发现

  • 14%为F0,32%为F1,18%为F2,22%为F3,13%为F4(肝硬化);48% NAS≥5。
  • FIB-4预测进展期纤维化汇总AUC为0.80(95%CI 0.79-0.81),拉丁美洲最低0.75(0.71-0.79),MENA最高0.84(0.82-0.87)。
  • ELF预测进展期纤维化汇总AUC为0.77(0.76-0.79),欧洲最低0.72(0.69-0.76),北美最高0.80(0.78-0.82)。
  • LSM预测进展期纤维化汇总AUC为0.84(0.83-0.85),除北美0.78(0.76-0.81)外各地区相似。
  • FAST预测进展期纤维化AUC为0.75(0.74-0.76),Agile-3+为0.87(0.86-0.88),各地区表现相似;Agile-4预测肝硬化AUC为0.90(0.89-0.91),北美最低0.85(0.83-0.87),MENA最高0.96(0.94-0.98)。

临床怎么用

  • 临床选用无创检测评估MASLD纤维化时需考虑地区性能差异。
  • Agile-3+和Agile-4复合评分在全球范围内准确性最高,可优先考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent worldwide. Performance of non-invasive tests (NITs) in patients with MASLD recruited from different regions of the world was evaluated. METHODS: MASLD patients with liver biopsies and NIT data [fibrosis-4 index (FIB-4), enhanced liver fibrosis (ELF), and liver stiffness measurement (LSM)] were enrolled through the Global NASH Council collaboration (G-MASLD). FibroScan-AST (FAST) and Agile-3+/Agile-4 were calculated. NITs' performance for predicting ≥F2 (significant fibrosis), ≥F3 (advanced fibrosis), or cirrhosis (F4) was determined in patients from different regions. RESULTS: A total of 17,792 MASLD patients from 41 countries were included: 14% had F0, 32% F1, 18% F2, 22% F3, 13% F4 (cirrhosis); 48% NAS ≥5. Advanced fibrosis prediction by NITs was variable across regions for FIB-4 [pooled AUC (95% CI)=0.80 (0.79-0.81)], the lowest in Latin America [0.75 (0.71-0.79)], the highest in MENA [0.84 (0.82-0.87)], and ELF [pooled AUC=0.77 (0.76-0.79)], the lowest in Europe [0.72 (0.69-0.76)], the highest in North America [0.80 (0.78-0.82)]. Prediction of advanced fibrosis by LSM [pooled AUC=0.84 (0.83-0.85)] was similar across regions except North America [0.78 (0.76-0.81)]. In addition, FAST [AUC=0.75 (0.74-0.76)] and Agile-3+ [AUC=0.87 (0.86-0.88)] performed similarly across regions. Similar trends were observed for the NITs predicting significant fibrosis. Finally, the accuracy of Agile-4 for predicting cirrhosis [AUC=0.90 (0.89-0.91)] was the lowest in North America [0.85 (0.83-0.87)], the highest in MENA [0.96 (0.94-0.98)]. CONCLUSIONS: The diagnostic performance of common NITs for fibrosis in MASLD varies across the world. In the large multinational G-MASLD sample, the most accurate NITs were Agile-3+ and Agile-4 composite scores.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Younossi ZM, de Avila L, Petta S, et al. Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study. Hepatology. 2025. PMID: 41100867. doi:10.1097/HEP.0000000000001564

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。